Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease
Paul Rutgeerts(KU Leuven), William J. Sandborn(University of San Diego), Jean‐Frédéric Colombel(Mount Sinai Hospital), Daphne Chan(Janssen (United States)), Brian G. Feagan(Western University), Yinghua Lang, Douglas C. Wolf(Atlanta Gastroenterology Associates), Philippe Szapary(Cedars-Sinai Medical Center), Paul Pollack(Reckitt Benckiser (United States)), Omoniyi J. Adedokun(Western University), Jewel Johanns(Johnson & Johnson (United States)), Christopher Gasink(Janssen (United States))
Cited by 181
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Crohn's disease
|The Lancet|2012|2.1k